CCRM
Arif Khan currently holds the position of Operations Supervisor at CCRM since November 2023, following a diverse career at Apotex Inc. where roles included Technical Writer for MES SOD, Operations Leader, and Production Operations in the Manufacturing sector from March 2017 to November 2023. Previous experience includes serving as a Pharmaceutical Processing Operator and Component Prep Operator at Septodont from November 2015 to February 2017, as well as working in Quality Assurance roles at Joriki Inc. and Elysium Pharmaceuticals Ltd. Arif Khan holds a Postgraduate Degree in Pharmaceutical Science Technology and a Graduate Certificate in Project Management from Durham College, along with a Bachelor of Pharmacy from Gujarat Technological University.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.